Zobrazeno 1 - 10
of 153
pro vyhledávání: '"L K, Shawver"'
Autor:
Kai Wang, Doron Lipson, L. K. Shawver, Phillip J. Stephens, Gary A. Palmer, V.A. Miller, Siraj M. Ali, J.S. Ross, Deborah A. Zajchowski, Roman Yelensky
Publikováno v:
Gynecologic Oncology. 130:554-559
Objective Targeted next generation sequencing (NGS) was evaluated for its ability to identify unanticipated targetable genomic alterations (GA) for patients with relapsed ovarian epithelial carcinoma (OC). Methods DNA sequencing was performed for 332
Publikováno v:
Clinical Cancer Research. 21:POSTER-TECH
Purpose: Despite major progress in the molecular characterization of ovarian cancers (OC), women with recurrent, advanced stage OC continue to be treated with cytotoxic chemotherapy agents that have poor overall response rates. This contrasts with th
Autor:
B. C. Langton, H.-L. C. Liu, D. L. Parkes, M. Longhi, M. P. Mcgrogan, L. A. Chao, J. W. Brandis, S. S. Elliger, L. K. Shawver, Jian-Ai Xuan
Publikováno v:
Biochemical and Biophysical Research Communications. 211:792-803
We describe the chimerization of a monoclonal antibody directed against the c-erbB-2 protein using a novel PCR method for cloning immunoglobulin variable region genes. We also describe the characterization of the chimera and show its potential use fo
Publikováno v:
Molecular and Cellular Biology. 10:4155-4162
To study the relationship between oncogenesis by v-src and normal cellular signalling pathways, we determined the effects of v-src on 3T3-TNR9 cells, a Swiss 3T3 variant which does not respond mitogenically to tumor promoters such as 12-O-tetradecano
Autor:
D B, Mendel, R E, Schreck, D C, West, G, Li, L M, Strawn, S S, Tanciongco, S, Vasile, L K, Shawver, J M, Cherrington
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(12)
SU5416, a selective inhibitor of the tyrosine kinase activity of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR, is currently in Phase III clinical trials for the treatment of advanced malignancies. In cellular assays, SU5416 inhibi
Autor:
A D, Laird, P, Vajkoczy, L K, Shawver, A, Thurnher, C, Liang, M, Mohammadi, J, Schlessinger, A, Ullrich, S R, Hubbard, R A, Blake, T A, Fong, L M, Strawn, L, Sun, C, Tang, R, Hawtin, F, Tang, N, Shenoy, K P, Hirth, G, McMahon, Cherrington
Publikováno v:
Cancer research. 60(15)
Vascular endothelial growth factor, fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) and their cognate receptor tyrosine kinases are strongly implicated in angiogenesis associated with solid tumors. Using rational drug design
Autor:
D B, Mendel, A D, Laird, B D, Smolich, R A, Blake, C, Liang, A L, Hannah, R M, Shaheen, L M, Ellis, S, Weitman, L K, Shawver, J M, Cherrington
Publikováno v:
Anti-cancer drug design. 15(1)
Angiogenesis, or the sprouting of new blood vessels, is a central process in the growth of solid tumors. For many cancers, the extent of vascularization of a tumor is a negative prognostic indicator signifying aggressive disease and increased potenti
Publikováno v:
Advances in cancer research. 79
Angiogenesis, the sprouting of new blood vessels, plays a role in diverse disease states including cancer, diabetic retinopathy, age-related macular degeneration, rheumatoid arthritis, psoriasis, atherosclerosis, and restenosis. With regard to cancer
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(4)
TAB-250 and BACH-250 are murine and human chimeric antibodies directed at the extracellular domain of the gp185c-erb-2 (HER2/neu) growth factor receptor overexpressed in a variety of tumor types, including ovarian and breast carcinoma. The ribosome-i
Autor:
T A, Fong, L K, Shawver, L, Sun, C, Tang, H, App, T J, Powell, Y H, Kim, R, Schreck, X, Wang, W, Risau, A, Ullrich, K P, Hirth, G, McMahon
Publikováno v:
Cancer research. 59(1)
SU5416, a novel synthetic compound, is a potent and selective inhibitor of the Flk-1/KDR receptor tyrosine kinase that is presently under evaluation in Phase I clinical studies for the treatment of human cancers. SU5416 was shown to inhibit vascular